{"id":"NCT00687401","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612)","officialTitle":"A Multi-center, Open Label Trial Evaluating the Efficacy , SAfety and the Impact on QUAlity of Life of Infliximab TherapY in Patients With Moderate-to-severe Psoriasis Not Responding to Standard or Biologic Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-06","primaryCompletion":"2009-05","completion":"2009-05","firstPosted":"2008-05-30","resultsPosted":"2010-12-24","lastUpdate":"2017-04-11"},"enrollment":215,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"Infliximab","otherNames":["Remicade, SCH 215596"]}],"arms":[{"label":"Infliximab 5 mg/kg","type":"EXPERIMENTAL"}],"summary":"Subjects with moderate-to-severe chronic psoriasis not responding to standard or biologic therapy will be eligible to enroll in this study. Subjects will receive infliximab infusions (5 mg/kg of body weight) at Weeks 0, 2, 6, and 14 followed by a 12-week follow-up period. The efficacy of infliximab will be evaluated by the Psoriasis Area and Severity Index (PASI).","primaryOutcome":{"measure":"Number of Participants Who Achieve a Greater Than or Equal to 75% Improvement in Psoriasis Area and Severity Index (PASI) Score","timeFrame":"10 weeks","effectByArm":[{"arm":"Intent to Treat Population","deltaMin":111,"sd":null},{"arm":"Per Protocol Population","deltaMin":111,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":13},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":159},"commonTop":["pyrexia","arthralgia"]}}